ArticleResearch and practice in thrombosis and haemostasis2025
Direct oral anticoagulant rivaroxaban for secondary prevention of catheter-related thrombosis in children with intestinal failure: real-life data.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rivaroxaban as Secondary Thromboprophylaxis in Pediatric Patients With Short Bowel Syndrome.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Catheter-related thrombosis (CRT) affects 20% to 57% of pediatric patients with intestinal failure (IF) on long-term parenteral nutrition with risk of venous access loss. Subcutaneous low-molecular-weight heparin is burdensome, with 35% of long-term treated children experiencing recurrent thrombosis. Data on the direct oral anticoagulant (DOAC) rivaroxaban in patients with IF are limited. Objectives: This study aimed to evaluate the characteristics and outcomes of children with IF receiving rivaroxaban for secondary prevention of CRT. Methods: We conducted a multicenter, retrospective longitudinal cohort study in children (0-17 years) with IF treated with rivaroxaban between July 2021 and May 2025. Clinical, diagnostic, imaging, and laboratory data were collected from medical records and analyzed. The study was approved by the institutional ethics board (709/2023BO2). Results: The study included 26 children; 15 children switched to anticoagulation with rivaroxaban to improve adherence due to incompliance with subcutaneous application. Median follow-up until the last imaging assessment was 436 days. In 11 children (42%), rivaroxaban dosage was adjusted due to insufficient drug levels. Two patients demonstrated CRT, corresponding to a rethrombosis rate of 7.7% or 0.2/1000 catheter days. Four patients (15%) experienced intestinal bleeding. Conclusion: This is the first study to provide real-life insights into the use of the DOAC rivaroxaban in children with intestinal failure, demonstrating its potential for secondary CRT prevention and child-friendly administration with very low rethrombosis rate. However, dose adjustments based on therapeutic drug monitoring might be necessary due to heterogeneous variability in absorption. Future prospective and comparative trials are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.